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Abstract
Engineered osteogenic constructs for bone repair 
typically involve complex and costly processes for 
cell expansion. Adipose tissue includes mesenchymal 
precursors in large amounts, in principle allowing for 
an intraoperative production of osteogenic grafts and 
their immediate implantation. However, stromal vascular 
fraction (SVF) cells from adipose tissue were reported to 
require a molecular trigger to differentiate into functional 
osteoblasts. The present study tested whether physiological 
doses of recombinant human BMP-2 (rhBMP-2) could 
induce freshly harvested human SVF cells to generate 
ectopic bone tissue. Enzymatically dissociated SVF 
cells from 7 healthy donors (1 x 106 or 4 x 106) were 
immediately embedded in a fibrin gel with or without 
250 ng rhBMP-2, mixed with porous silicated calcium-
phosphate granules (Actifuse®, Apatech) (final construct 
size: 0.1 cm3) and implanted ectopically for eight weeks 
in nude mice. In the presence of rhBMP-2, SVF cells not 
only supported but directly contributed to the formation of 
bone ossicles, which were not observed in control cell-free, 
rhBMP-2 loaded implants. In vitro analysis indicated that 
rhBMP-2 did not involve an increase in the percentage of 
SVF cells recruited to the osteogenic lineage, but rather 
induced a stimulation of the osteoblastic differentiation 
of the committed progenitors. These findings confirm the 
feasibility of generating fully osteogenic grafts using an 
easily accessible autologous cell source and low amounts 
of rhBMP-2, in a timing compatible with an intraoperative 
schedule. The study warrants further investigation at an 
orthotopic site of implantation, where the delivery of 
rhBMP-2 could be bypassed thanks to the properties of 
the local milieu.
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osteogenesis; tissue engineering.
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Introduction
The standard of care in the treatment of bone defects 
in orthopaedic, trauma or reconstructive surgery is the 
transplantation of autologous bone grafts. Alternative 
options are the implantation of allografts or osteoconductive 
materials, the local treatment with osteoinductive growth 
factors such as BMP-2 or BMP-7, or combinations thereof 
(Berner et al., 2011; De et al., 2007; Saxer F et al., 2010). 
The engineering of osteogenic bone graft substitutes based 
on osteoconductive scaffolds combined with autologous 
osteoprogenitors (mesenchymal stromal cells, MSC) as a 
biologically active component could provide an attractive 
alternative, but its translation into clinical practice has 
proven to be highly challenging (Berner et al., 2011; 
Cuomo et al., 2009; Evans et al., 2007). Low MSC 
numbers found in the bone marrow generally require a 
step of cell expansion for graft manufacturing. This not 
only is known to be associated with a progressive loss of 
osteogenic differentiation capacity (Banfi et al., 2000), but 
also requires processing under costly and tightly regulated 
Good Manufacturing Practice (GMP) conditions. Thus, 
cost-effectiveness of the classical bone tissue engineering 
paradigm still needs to be verified (Meijer et al., 2007).
 One possible solution proposed to overcome the 
limitations above is based on the 3D expansion of MSC 
directly within porous scaffolds (Braccini et al., 2005). This 
was shown to reduce intra-individual differences, increase 
quality of grafts and streamline manufacturing in perfusion 
bioreactors, with the potential to introduce automation 
and thus reduce costs (Martin et al., 2009). Another 
approach has more radically addressed the problem, by 
trying to eliminate the expansion phase, i.e. reducing the 
manufacturing process to a one-step surgical procedure. 
Such an intra-operative approach poses the essential 
requirements to identify an autologous source of cells 
that have (i) intrinsic osteogenic capacities in vivo without 
prior culture or osteoinduction and (ii) are available in 
sufficient numbers directly upon isolation. Freshly isolated 
bone marrow-derived cells, possibly harvested using 
a reamer-irrigator-aspirator (Cox et al., 2011; Stafford 
and Norris, 2010), concentrated by immunoselection 
(Aslan et al., 2006) or modified genetically (Evans et al., 
2007), have been proposed to be directly used for bone 
repair. Despite the promising data collected so far, the 
reproducible collection of a sufficient number of MSC 
across different patients remains to be demonstrated. The 
freshly-isolated stromal vascular fraction (SVF) of human 
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adipose tissue represents a possibly better cell source for a 
one-step surgical procedure, given its up to 500-fold larger 
number of clonogenic progenitors per volume of tissue 
sample compared to human bone marrow (Fraser et al., 
2006; Scherberich et al., 2007). Two studies (Helder et 
al., 2007; Vergroesen et al., 2011) tested bone formation 
by autologous SVF cells, intraoperatively processed to 
generate grafts implanted in a goat spinal fusion model. 
Those studies demonstrated a superior bone healing when 
implants were loaded with SVF cells, but the model was 
not designed to assess the direct osteogenic properties of 
the SVF-based grafts. Our group recently demonstrated 
that ectopic implantation in nude mice of human SVF cells 
seeded on porous hydroxyapatite scaffolds results in the 
formation of human origin blood vessels and dense osteoid 
matrix, but no ‘frank’ bone formation (Müller et al., 2010). 
These findings suggested that, in the absence of in vitro 
commitment, additional cues (e.g. osteoinductive factors) 
might be needed to support ectopic bone tissue generation 
in vivo.
 In the present study, recombinant human bone 
morphogenetic protein-2 (rhBMP-2) was therefore used as 
an osteoinductive stimulus (Chen et al., 2004; Jeon et al., 
2008) for the implanted SVF cells, at doses known to be 
insufficient to induce by themselves bone tissue formation 
(Fujimura et al., 1995). RhBMP-2 was introduced in fibrin-
ceramic-based constructs simultaneously with the freshly-
isolated/SVF cells and immediately implanted ectopically 
in nude mice. Bone formation and the contribution of 
SVF cells to this process were studied 8 weeks after 
implantation. In vitro experiments were also performed to 
address whether rhBMP-2 enhances SVF cell osteogenic 
differentiation and/or the osteogenic recruitment of 
clonogenic SVF populations.
Material and Methods
Cell isolation
Adipose tissue, in the form of liposuction or excised fat 
samples, was obtained from 7 healthy female donors 
following informed consent and according to a protocol 
approved by the local ethical committee (EKBB, Ref. 
78/07). Minced tissue from excised fat samples or 
lipoaspirates were processed as previously described 
(Güven et al., 2011; Müller et al., 2010) and the cell 
pellets resuspended in complete medium (CM), consisting 
of α-MEM supplemented with 10 % of foetal bovine 
serum (FBS), 1 % HEPES, 1 % sodium pyruvate and 1 % 
Penicillin-Streptomycin Glutamate (100x) solution (all 
from Gibco, www.invitrogen.com).
Cell characterisation
Fluorescence activated cell sorting (FACS)
SVF cells were analysed by cytofluorimetry with antibodies 
to CD105, CD90 and CD73 (mesenchymal markers), CD31 
and CD34 (endothelial markers), the monocytic marker 
CD14 and the pan-haematopoietic marker CD45 (anti-
CD105 antibody from AbD Serotec, www.abdserotec.
com, all others from Becton Dickinson Bioscience, www.
bdbiosciences.com), as previously described (Gronthos et 
al., 2001; Güven et al., 2011).
Frequency of clonogenic cells
The ratio of colony forming unit-osteoblasts (CFU-o) 
to the total number of formed colonies (colony forming 
unit-fibroblasts, CFU-f) (Friedenstein et al., 1970; 
Baksh et al., 2003) was determined by plating 100 SVF 
cells/well into six well plates. Cells were cultured with 
CM or osteogenic medium (OM), consisting of CM 
supplemented with 100 nM dexamethasone, 10 mM beta-
glycerophosphate, and 0.05 mM ascorbic-acid-2-phosphate 
(Sigma-Aldrich, www.sigmaaldrich.com) for 14 d, in the 
presence or absence of the indicated concentration of 
rhBMP-2 (produced in CHO cells by R&D Systems, www.
rndsystems.com). CFU-o were defined as colonies stained 
positive for alkaline phosphatase (ALP) activity, using a 
commercially available kit (104-LL kit, Sigma-Aldrich). 
The CFU-o/CFU-f ratio was determined following counter 
staining with buffered neutral red solution (N6264, Sigma-
Aldrich), which allowed counting of the total number of 
CFU-f.
In vitro stimulation with rhBMP-2
SVF cells were plated on tissue culture plastic and grown 
to confluence in the presence of CM. Cells were then 
cultured for 14 d with either CM or OM, alone or further 
supplemented with either 50 or 500 ng/mL rhBMP-2 
(produced in bacteria as previously described (Weber et al., 
2002), hereafter referred to as own-produced, or produced 
in mammalian CHO cells by R&D Systems) and analysed 
by reverse transcriptase real time polymerase chain reaction 
(RT-rt-PCR). Cells were then treated with lysis buffer 
(Qiagen, http://www.qiagen.com) enriched with 1/100 
(V/V) β-mercaptoethanol (Sigma-Aldrich). RNA was 
extracted by using a NucleoSpin® RNA II kit (Macherey-
Nagel, http://www.mn-net.com). The RNA was eluted 
in RNase-free water and transcription into cDNA was 
performed as previously described (Barbero et al., 2003). 
The samples were analysed by using a GeneAmp® PCR 
System 9600 (Perkin Elmer, www.perkinelmer.com) and 
the transcription levels of osteopontin (OP) and osteocalcin 
(OC) quantified, with glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as reference housekeeping gene 
(Frank et al., 2002). SVF cells were similarly plated on 
tissue culture plastic, grown to confluence and cultured for 
7 d with CM, alone or further supplemented with 500 ng/
mL BMP-2 (R&D Systems). Cells were then detached with 
trypsin (Invitrogen) and analysed by cytofluorimetry with 
fluorochrome-conjugated antibodies to ALP and OC (both 
from R&D systems, www.rndsystems.com).
Generation and assessment of SVF cells-fibrin-
ceramic constructs
One or four millions SVF cells were suspended in 
the fibrinogen phase (30 µL) of a polymerising fibrin 
gel (Tisseel®, Baxter, www.baxter.com), as described 
previously (Bensaid et al., 2003; Müller et al., 2010), with 
or without addition of 250 ng of rhBMP-2 (own-produced 
or from R&D Systems). Briefly, following mix with the 
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thrombin phase (30 µL), the solution was poured onto a 
volume of approx. 0.06 cm3 of hydroxyapatite granulates 
of 1-2 mm size (Actifuse® ABX, ApaTech, www.apatech.
com) pre-stacked in the wells of a 96-well plate. After 
1-2 min, when the gels polymerised, the volume of the final 
constructs was 0.1 cm3. Those constructs were covered with 
CM and transferred into a humidified incubator (37 °C, 5 % 
CO2) for 10 min. Directly after fabrication, some constructs 
were incubated for 2 h at 37 °C in a 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-
Aldrich) solution at a final concentration of 0.05 mg/
mL and the distribution of the blue/purple metabolised 
substrate of MTT was inspected macroscopically to assess 
cell viability. Other constructs were fixed overnight in 4 % 
formalin, paraffin-embedded, sectioned and stained with 
haematoxylin/eosin (H&E) for qualitative assessment of 
the spatial distribution of the seeded cells. The remaining 
constructs were implanted in nude mice as described below.
In vivo implantation in nude mice and explant 
analysis
The maintenance, surgical treatment and sacrifice of 
animals were performed in accordance with the guidelines 
of the local veterinary agency (“Kantonales Veterinäramt 
Basel-Stadt”, permission #1797). Constructs were 
implanted in the subcutaneous tissue of nude athymic 
mice (CD1 nu/nu, Charles River, www.criver.com) and 
harvested after eight weeks following mouse sacrifice 
Fig. 1. Characterisation of cells and constructs in vitro. (A) Cytofluorimetric analysis of freshly-isolated SVF cells 
derived from 7 donors. For every CD marker, the average percentage of cells positive for the marker is plotted. 
Error bars represent standard deviations. (B) Representative picture of a tetrazolium-based metabolic staining (MTT 
assay) performed on SVF cells-fibrin gel-ceramic granules constructs to demonstrate the distribution of viable cells. 
(C and D) Macroscopic (C) and microscopic (D) pictures of haematoxylin/eosin staining performed on histological 
sections of decalcified, paraffin-embedded samples.
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by inhalation of CO2. Tissues were fixed in 4 % formalin 
overnight, subjected to slow decalcification in 7 % w/v 
EDTA and 10 % w/v sucrose (both from Sigma-Aldrich) 
at 37 °C on an orbital shaker for 7-10 d and paraffin-
embedded. Samples were then cross-sectioned (12 µm 
thickness) and processed for histological, histochemical 
and immunohistochemical stainings as follows. Standard 
H&E staining and Masson’s trichrome staining (Kit 
Trichrome de Masson-Vert lumière, Réactifs RAL, 
www.ral-diagnostics.fr) were performed to identify 
bone tissue formation and maturation stage. Safranin-O 
staining allowed investigating the presence of sulphated 
proteoglycans inside the construct, characteristic of 
cartilaginous tissue. Tartrate resistant alkaline phosphatase 
(TRAP) staining (leukocyte acid phosphatase kit, Sigma-
Aldrich) was used to identify osteoclasts, while the 
presence of osteoblastic cells and osteoid structures was 
assessed by immunostaining for human bone sialoprotein 
(BSP, Immundiagnostik AG, www.immundiagnostik.
com) (Minkin, 1982; Papadimitropoulos et al., 2011). 
The presence of donor-derived, human blood vessels was 
demonstrated by immunostaining with a biotin-conjugated 
antibody for human CD34 (Abcam, www.abcam.com), as 
previously described (Scherberich et al., 2007). All human 
cells in the explants were identified by chromogenic in 
situ hybridisation for the human-specific sequence ALU, 
using a biotin-conjugated DNA probe (ZytoVision, http://
zytovision.com), as previously described (Müller et al., 
2010; Roy-Engel et al., 2001).
Results
The percentage of CFU-f in the SVF preparations 
from different human adipose tissue samples averaged 
14.7 ±6.8 % (n = 4). The fractions of different SVF 
subpopulations were highly variable across different 
donors, as assessed by the large standard deviations in the 
percentage of positive cells for different typical surface 
markers (Fig. 1A) and in accordance with previous reports 
(Müller et al., 2009; Müller et al., 2010). Once embedded 
in a fibrin gel around ceramic granules, SVF cells were 
viable and homogenously distributed throughout the 
construct, as evidenced by MTT metabolic staining (Fig. 
1B). The structure of the construct was investigated by 
H&E staining of sections of decalcified samples (Fig. 1C 
and D). It allowed visualising the structural components 
of the constructs prior to implantation, including the fibrin 
Fig. 2. Comparison of in vivo bone formation. Representative fluorescence microscopy pictures of histology sections 
of explanted, fixed and decalcified constructs. Experimental conditions are indicated in the figure. The values provided 
for each experimental condition is the ratio of donors exhibiting bone formation in vivo by the total number of donors 
tested. Scale bars represent 200 µm and (b) indicates bone tissue. * indicates a significant difference (p < 0.05) in 
bone formation as tested by Kruskal-Wallis test followed by post-hoc Dunn’s tests.
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gel (pink stain in Fig. 1C and D), the embedded cells (blue 
stain in Fig. 1D) and the porous ceramic granules (void 
spaces in decalcified samples, Fig. 1C).
 In the absence of incorporated BMP-2 and independent 
of the initial cell density (1 or 4 million SVF cells 
per 100 mm3 construct), constructs explanted after 
subcutaneous implantation for 8 weeks in nude mice did 
not display evidence of frank bone tissue formation in any 
specimen, as assessed by H&E staining (data not shown) 
and by fluorescence microscopy (Fig. 2, left column) of 
sections taken at different depths. These findings are in 
accordance with our previously published results (Müller 
et al., 2010). The addition of 250 ng of rhBMP-2 inside the 
fibrin gel in conjunction with 4 million SVF cells, resulted 
in the formation of ectopic bone tissue, at a frequency (5 
out of 7 donors) which was significantly different from the 
corresponding condition in the absence of rhBMP-2 (0 out 
of 7 donors) (Kruskal-Wallis with post-hoc Dunn’s test). 
The use of a lower number of cells (1 million SVF cells) 
in the presence of rhBMP-2 also resulted in bone tissue 
formation, at a frequency (1 out of 3 donors) which was 
not significantly different from the one obtained with the 
higher cell number (Fig. 2).
 Bone tissue formation was confirmed by H&E staining 
both around the entire construct, in between the ceramic 
granules and within their pores (Fig. 3A, black arrows). 
Bone tissue displayed the typical features of an ‘ossicle’ 
structure, including a dense collagenous matrix with 
embedded osteocytes and a rim of osteoblasts in contact 
with the osteoid tissue (Fig. 3B). Masson’s trichrome 
staining further qualified that the bone tissues was at 
various stages of maturation, with local spots of red stained 
regions, indicating the presence of elastic proteins and 
characteristic of a more mature bone tissue (Fig. 3C, black 
arrow). Neighbouring already developed bone ossicles, 
areas of pre-osteoid tissue were also identified by positive 
immunostaining for bone sialoprotein (Fig. 3D, black 
arrow). As a control group, implantation of ceramic-fibrin-
rhBMP-2 constructs without cells resulted in a merely 
fibrous tissue with no evidence of bone formation (data 
not shown).
Fig. 3. Characterisation of newly-formed bone tissue. Histological analysis of sections of explanted, fixed and 
decalcified constructs seeded with 4 x 106 SVF cells and rhBMP-2. (A) Haematoxylin/eosin. Arrows show newly-
formed bone tissue both in the pores of granules and in a shell around the construct. (B) Higher magnification of the 
same sections showing compact bone matrix (b) and osteocytes embedded therein. (C) Masson’s trichrome staining. 
The green dye stains dense collagenous matrix identifying bone tissue (b) in contact with the ceramic granules (gr.), 
with various stages of maturation, in particular zones with red staining characterising elastic proteins (arrows). 
(D) Immunostaining for BSP. The arrow indicates a zone with BSP-positive osteoblastic cells, where initial bone 
formation is on-going. Areas with mature bone tissue (b) do not contain osteoblastic cells.
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 In order to study the contribution of implanted human 
SVF cells to the formation of tissue inside the construct, 
in situ hybridisation for human-specific ALU sequences 
was performed. Cells of human origin were identified both 
embedded within the bone matrix (putative osteocytes, 
black arrow in Fig. 4A) as well as at the bone matrix 
deposition front (putative osteoblasts, open arrow in 
Fig. 4A). ALU staining was also positive in the lumen of 
capillaries (putative endothelial cells, red circle in inset, 
Fig. 4A). The contribution of human vascular cells from 
the SVF to blood vessel formation was further confirmed 
by immunostaining for human CD34 (Fig. 4B, open 
arrows). The presence of erythrocytes in the lumen of 
the human capillary structures demonstrated functional 
connection with the host vasculature. Negative safranin-O 
staining indicated the absence of structures containing 
cartilage-specific glycosaminoglycans (Fig. 4C). TRAP 
staining identified the presence of multinucleated cells, 
likely of host origin, in contact with the newly formed 
bone (putative osteoclasts, arrow in Fig. 4D), suggesting 
an active remodelling process.
 We next investigated the effect of rhBMP-2 on the 
percentage of osteoprogenitors recruited in vitro within the 
SVF cell population and the level of osteogenic induction 
of those osteoprogenitors in vitro. The CFU-o/CFU-f ratios, 
representing the fraction of clonogenic SVF cells displaying 
osteogenic properties, were higher in OM than in CM, but 
were not affected by rhBMP-2 at both tested concentrations 
Fig. 4. Characterisation of the contribution of SVF cells to tissue formation. Histological analysis of sections of 
explanted, fixed and decalcified constructs seeded with 4 x 106 SVF cells and rhBMP-2. (A) In situ hybridisation 
for human-specific ALU sequences. Osteocytes (black arrows) and lining osteoblasts (open arrows) of human origin 
are identified by their nuclear ALU staining. Inset shows ALU nuclear staining of human endothelial cells at the 
level of human capillaries (red dashed line). (B) Immunostaining for human CD34 shows human blood vessels (bv, 
open arrows), filled with erythrocytes. (C) Safranin-O staining with no specific red staining indicative of sulphated 
proteoglycans and therefore of the generation of cartilaginous tissue inside the constructs. (D) TRAP staining showing 
the presence of multinucleated, osteoclastic cells in contact with newly formed bone (arrow). (b) indicates bone and 
(gr.) ceramic granules.
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Fig 5. Legend on next page.
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(Fig. 5A). The level of osteogenic induction of SVF cells in 
vitro was assessed by the mRNA expression of osteoblastic 
markers, namely BSP and OP. The expression of these 
genes was not affected by medium supplementation with 
50 ng/mL rhBMP-2, whereas it was consistently enhanced 
by the use of 500 ng/mL rhBMP-2, independently of the use 
of CM or OM (Fig. 5B). To confirm this trend in the effect 
of rhBMP-2 on the differentiation of the osteoprogenitors, 
the effect of 500 ng/mL rhBMP-2 on cells cultured with 
CM was tested by cytofluorimetry and compared to 
untreated cells (negative control) and cells cultured with 
OM (positive control). RhBMP-2 significantly increased 
the differentiation of osteoprogenitors (one-way ANOVA 
test followed by post-hoc Newman-Keuls tests), at levels 
similar to OM, based on the expression of ALP (Fig. 5C) 
and on cells co-expressing ALP and OC (Fig. 5D).
 All results generated with own-produced or R&D-
produced rhBMP-2, as specified in the Methods section, 
displayed consistent trends and no difference in efficiency 
at the same tested concentrations.
Discussion
This study validates an intraoperative manufacturing 
concept for the generation of grafts with osteogenic/
vasculogenic potential derived from human adipose tissue. 
The formation of bone tissue was shown to require the 
delivery of a low dose of rhBMP-2, which could not induce 
ectopic ossification by itself. The reproducibility of bone 
tissue formation might well be improved by increasing the 
density of implanted SVF cells, which not only supported 
but directly contributed to bone tissue formation. The in 
vitro results suggest that the mode of action of rhBMP-2 
did not involve an increase in the percentage of SVF cells 
recruited to the osteogenic lineage, but rather a stimulation 
of the osteoblastic differentiation of the committed 
progenitors.
 Previous reports demonstrated that SVF cells, 
freshly isolated from adipose tissue and immediately 
implanted, can enhance bone healing in orthotopic 
experimental animal models (reviewed in Scherberich 
et al., 2010). Autologous SVF cells have also been used 
in an intraoperative approach in a few clinical cases, 
demonstrating safety and a favourable clinical outcome 
(Lendeckel et al., 2004; Pak, 2011). However, in all these 
studies, the direct contribution of the implanted cells 
to bone formation was not addressed and therefore the 
intrinsic osteogenic capacity of freshly harvested SVF cells 
had not yet been demonstrated. The experimental setup 
used in the present work, namely an ectopic implantation 
site in a nude mouse model, allowed us to investigate the 
fate and mode of action of the implanted human SVF cells 
and therefore to conclude that SVF cells can directly form 
bone tissue, but only when stimulated in situ by rhBMP-2.
 The induction of bone formation by BMPs in vivo was 
described for the first time in 1965 (Urist, 1965). Numerous 
in vitro and in vivo studies have later demonstrated enhanced 
bone repair by rhBMP-2, which is now FDA-approved in 
spinal, trauma and maxillo-facial surgery (Govender et 
al., 2002; Hsu and Wang, 2008; Jones et al., 2006; Smith 
et al., 2008). The clinical use of rhBMP-2 is based on the 
principle of induction of osteogenesis by resident precursor 
cells and requires very high and non-physiological doses, 
which have been reported to be associated with aberrant 
bone formation (Deutsch, 2010), neurotoxicity (Smith et 
al., 2008) or cancer development (Carragee et al., 2011). 
As compared to commercially available products, which 
contain 1.5 mg/mL rhBMP-2, the concentration used in 
the present study (2.5 µg/mL construct) was about three 
orders of magnitude lower. The dose, which to the best 
of our knowledge is lower than the minimal one ever 
reported for stimulation of adipose-derived cells in vivo 
(Jeon et al., 2008), was not intrinsically associated with 
osteoinductivity and supported bone formation only by 
acting in concert with the implanted cells. Moreover, it 
cannot be excluded that the combination of implanted 
human cells and rhBMP-2 could have recruited resident 
cells from the host which may have directly contributed 
to bone formation in conjunction with implanted bone-
forming cells.
 The actual osteogenic responsiveness of mesenchymal 
stromal cells to BMPs, in particular for osteoprogenitors 
derived from adipose and bone marrow tissues, is still 
controversial. Indeed, while some groups reported no 
significant difference of bone formation after addition of 
rhBMP-2 (Chou et al., 2011; Diefenderfer et al., 2003; 
Osyczka et al., 2004; Zuk et al., 2011) or transfection with 
hBMP-2 gene (Peterson et al., 2005), some others reported 
induction of bone repair by BMP-2 stimulation of adipose-
derived osteoprogenitors (Jeon et al., 2008; Lee et al., 
2010). This discrepancy may result from factors such as the 
high inter-donor variability, the variety of animal models 
and experimental settings, as well as the doses of rhBMP-2 
Fig. 5. (on previous page) In vitro effect of rhBMP-2 on human SVF cells. (A) Effect of 2 different doses of rhBMP-2 
(50 and 500 ng/mL) on the CFU-o/CFU-f ratio of human SVF cells cultured with either complete medium (CM) or 
osteoblastic induction medium (OM). Experiments were performed in triplicates with cells from n = 6 independent 
donors. Average ±s.d. is represented. (B) Effect of 2 different doses of rhBMP-2 (50 and 500 ng/mL) on the expression 
levels of bone sialoprotein (BSP) or osteopontin (OP) mRNA. Results are represented as average ±s.d. of the ratio 
between marker expression levels and expression levels of GAPDH. Experiments were performed in duplicate with 
cells from n = 3 independent donors. (C and D) Effect of 500 ng/mL rhBMP-2 and OM on the percentage of cells 
expressing the osteoblastic markers alkaline phosphatase (ALP) (C) or ALP+osteocalcin (OC) (D). Experiments were 
performed with cells from n = 5 independent donors. Average ±s.d. is represented. * and ** indicate statistically 
significant differences (p < 0.05 and p < 0.01, respectively) as tested by one-way ANOVA test followed by post-hoc 
Newman-Keuls tests.
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used (Zara et al., 2011). Also age and sex of the donor seem 
to influence the osteogenic potential of osteoprogenitors 
(van Harmelen et al., 2003; Zhu et al., 2009), as well as 
their responsiveness to rhBMP-2 (Kim et al., 2008). Our in 
vitro results indicate that rhBMP-2 specifically stimulated 
the osteoblastic differentiation of SVF cells. No effect of 
rhBMP-2 on adipose-derived cell differentiation was seen 
with 50 ng/mL, confirming a previous report (Zuk et al., 
2011) showing no effect at doses ranging 10-100 ng/mL. 
We however demonstrated in this study, both at the gene 
expression and protein expression level, that a 500 ng/
mL concentration stimulated osteoblastic differentiation 
of adipose-derived cells. For the in vivo study, we used a 
cumulative dose of rhBMP-2 (2.5 µg/cm3 construct) which 
was in the same range as the total amount of rhBMP-2 
supplemented in vitro for the culture duration of 2 weeks 
(1.5 µg). However, considering the different release profiles 
(i.e., 3 repetitive doses for monolayer culture in vitro, 
versus burst release from the gel in vivo) and the different 
cell mixes (i.e., pure ASC in vitro, versus SVF cells 
containing mesenchymal, endothelial and haematopoietic 
populations in vivo), the effective concentration delivered 
to cells in the two models cannot be directly compared.
 Both bacteria- and mammalian cell-derived rhBMP-2 
were used in parallel in this study and demonstrated that 
the lack of response at 50 ng/mL was not due to the origin 
or glycosylation status of rhBMP-2. This confirmed our 
recent results showing that bacterial rhBMP-2 displays 
similar bioactivity for in vitro osteoblastic differentiation as 
compared to the medical grade, CHO cell-derived rhBMP-2 
from Medtronic (Hanseler et al., 2012). Interestingly, there 
have been promising results in enhancing bone formation 
by adipose tissue cells also by addition of vitamin D3 
(Song et al., 2011), alendronate (Wang et al., 2010) or 
platelet-rich plasma (Liu et al., 2008). Whether or not 
addition of these substrates, alone or in combination with 
rhBMP-2, could lead to a more reliable bone formation 
in the proposed setup will also have to be investigated. 
Finally, although rhBMP-2 was previously reported to 
have the potential to stimulate angiogenesis (Deckers et 
al., 2002; Peng et al., 2005), in our study the presence 
of human endothelial cells (positively stained for ALU 
sequences and for human CD34) in graft vascularisation 
did not appear to be increased in the presence of rhBMP-2 
(data not shown).
Conclusion
This study reinforces the feasibility of an intraoperative 
use of autologous SVF cells for bone regeneration. The 
approach requires only one surgical procedure, similar 
to autologous bone grafting but clearly with reduced 
morbidity at the donor site. Moreover, it does not require 
extensive processing and culture of the isolated cells, 
thereby also reducing the costs and regulatory burdens 
otherwise associated with advanced cellular therapies. 
The use of low doses of rhBMP-2 was essential in the 
ectopic model to drive osteoblastic differentiation of SVF 
progenitors, but could be bypassed upon implantation at 
an orthotopic site, in the context of a bone environment 
where such physiological amounts of BMPs are likely 
already present. Recent work on the established interaction 
between the immune system and osteoprogenitor cell 
function (Liu et al., 2011) also prompts for further studies 
in immunocompetent models with a proper onset of 
inflammatory processes. However, the introduction of 
alternative in vivo models requires the use of animal as 
opposed to human adipose-derived cells, which are known 
to have markedly different biological properties and 
osteogenic potential (Levi et al., 2011) and thus would limit 
the potential clinical relevance of the generated findings. 
In this regard, one of the most compelling challenges 
in the routine clinical implementation of this approach 
is related to the large variability in phenotype and bone 
forming capacity of human adipose-derived cells from 
different donors (Scherberich et al., 2007). Therefore, one 
additional effort will have to involve the identification of 
reliable quality control/potency markers of the implanted 
cells, in order to ultimately define the number of cells with 
a specific phenotype which should be introduced per unit 
of construct volume to ensure reproducible bone formation.
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Discussion with Reviewers
Reviewer I: These interesting findings need to be validated 
in bone defect models. In particular, the authors suggest 
that BMP-2 may not be required in orthotopic sites which 
could provide a favourable environment to promote 
osteoblastic maturation of MSCs. Likewise, we could 
assume that BMP-2 alone without cells in an environment 
rich in osteoblast progenitors may be sufficient to promote 
bone repair. These challenges could be addressed in bone 
lesions models in nude rats, which would allow the use of 
human MSCs.
Authors: This is a very good suggestion from the reviewer. 
We have indeed already initiated such a study in a femoral 
defect in nude rat to address this question. The study is 
currently in progress but preliminary data suggest that 
human SVF cells can generate bone tissue in the absence 
of BMP-2 in such a model. Comparison of the bone repair 
with SVF cells to acellular constructs loaded with only 
BMP-2 is also within the next series of experiments to be 
performed.
